This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!
Tekla Life Sciences Investors
HQL : NYSE : Financial
$27.57 -0.30 | -1.08%
Today's Range: 27.55 - 27.83
Avg. Daily Volume: 72,300
03/31/15 - 3:59 PM ET


HQL Peer Plot Chart

This chart compares HQL to the highest rated funds in its peer group of Sector - Health/Biotechnology funds. The above graph illustrates two key measures that investors should consider when assessing the investment potential of a particular fund. One of the key factors is how the fund has performed over the most recent reporting period, defined as the 1 year total return on the bottom axis. The second factor is the fund's reported expense ratio, on the right axis, which includes things like management fees. The best funds, with higher returns and lower expenses, stake out a position in the lower left part of this graph.

TOP RATED FUNDS : Sector - Health/Biotechnology
1 Year
3 Year
Health Care Select Sector SPDR XLV 5.64 23.31 27.98 0.15 1
iShares US Healthcare ETF IYH 6.16 23.30 28.27 0.45 2
Gabelli Healthcare & WellnessRx Tr GRX 6.62 15.28 27.79 1.65 3
iShares US Pharmaceuticals ETF IHE 11.23 29.26 29.64 0.45 4
Fidelity MSCI Health Care Index ETF FHLC 6.38 23.59 0.00 0.12 5
Vanguard HealthCare Index ETF VHT 6.39 23.71 28.80 0.12 6
First Trust Health Care AlphaDEX FXH 7.03 22.24 29.52 0.67 7
SPDR S&P Health Care Services ETF XHS 7.34 29.55 27.64 0.35 8
iShares US HealthCare Providers ETF IHF 7.49 32.60 26.08 0.45 9
Tekla Life Sciences Investors HQL 15.04 24.63 38.79 1.32 22
The above table compares the total return performance and expense ratio of Tekla Life Sciences Investors to the top rated funds within the Sector - Health/Biotechnology peer group. Tekla Life Sciences Investors ranks number 22 out of 29 Sector - Health/Biotechnology closed-end and exchange-traded funds that we rate.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Latest Stock Upgrades/Downgrades

Top Rated Stocks Top Rated Funds Top Rated ETFs